Good morning, everyone, and welcome to the Medicenna company presentation and KOL webinar. At this time, all participants are in a listen-only mode, and a question-and-answer session will follow the formal presentations. As a reminder, this event is being recorded, and a replay will be made available on the Medicenna website following the conclusion of the event. I would now like to turn the call over to Dr. Fahar Merchant, President and Chief Executive Officer of Medicenna. Please go ahead.
Thank you very much, Tara, and welcome to all of you who are joining us today at this KOL event. Before I proceed, let me mention that really important for us as a company to thank all the families, the patients, the clinical centers, sites that have participated in the clinical trial, and their valuable contributions to the ABILITY-1 clinical data that we will share with you today. As part of this presentation, I just want to mention that we will be making forward-looking statements and therefore encourage you to review our regulatory filings on SEDAR. Joining us today, and I think really important for us as a company to have the privilege of having the participation of two outstanding investigators, key opinion leaders in the field of cancer immunotherapy. First and foremost, we have Dr. Hussein Tawbi, who is a prominent international physician scientist in the immuno-oncology space.
At the moment, he is the Executive Director of Immuno-Oncology Clinical Drug Development Program at the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, perhaps the world's best cancer research center. Really privileged to have him. He is a recipient of several awards, has been part of numerous breakthrough therapies that have become now standards of care for different immune therapies. Also joining us is a young rising star from Portugal, Lisbon, Dr. André Mansinho, who is a principal investigator for the ABILITY study and has enrolled several patients in this clinical trial. He is the Director of Clinical Research at START Center for Cancer Care at the University of Lisbon. Then finally, myself, President and CEO of Medicenna.
Today's agenda, I will provide an introduction and a brief overview about MDNA11 and why we think it is such a differentiated molecule compared to the IL-2s that have been in development for the past three decades. Then I will pass it on to Dr. Hussein Tawbi, who will focus on unmet needs in immunotherapy and the potential role of MDNA11 to address those challenges. After that, Dr. Mansinho will present the phase I/II ABILITY study data and the clinical design and protocol, and of course, the data resulting from this particular study. Going back to Dr. Tawbi, he will provide us his contextualization, understanding of the data, and what the potential future direction might be for MDNA11. I will then conclude, and we will open the floor up for Q&A. As a company, Medicenna has really focused on building interleukins, very specifically interleukin-2, 4, and 13.
These have been engineered using directed evolution, and they come from the lab of Professor Garcia at Stanford University. These naked Superkines that we have licensed from Stanford have been brought into Medicenna, and since then, we've sort of dressed them up to generate what we call long-acting Superkines so that they can stay in the bloodstream much longer. We've also dressed them up by creating bifunctional Superkines and also masked them so that we are able to switch these Superkines right at the tumor site. We won't talk about BiSKITs or the T-MASK platform today, but we'll focus on the long-acting IL-2 superagonist. If you look at our platform right now, as you can see, around the IL-2 Superkine, we've got three assets.
The one that's the most advanced asset is MDNA11, and today we'll be focused on MDNA11, and particularly the ABILITY-1 study, where it is examining the potential for MDNA11 in a single-agent monotherapy setting, and then also in combination with Merck's KEYTRUDA. Here, I would like to acknowledge Merck for their generous contribution and clinical collaboration, and of course, the supply of KEYTRUDA that has been used to dose hundreds of doses to patients in this ABILITY-1 clinical trial. Separately, we have an MDNA11 superagonist study underway in neoadjuvant melanoma patients. This has been conducted by Dr. Paolo Ascierto and 12 other centers in Italy, and it's funded by the Fondazione Melanoma.
Using the IL-2, that is the key component in MDNA11, we have now recently created a bifunctional anti-PD1-IL-2 using the same IL-2 that's currently in MDNA11, and that program is currently in preclinical studies with the intent of entering clinical trials next year. Then finally, using the same IL-2 as in MDNA11, we have recreated an IL-2 super antagonist, using the IL-2 super agonist as the backbone. The intent there being to really block IL-2/15 signaling so that we can address patients that need treatment for autoimmune disease. Today, I think the key message is, why are we developing an IL-2 which is not alpha, but beta enhanced?
I think we are all aware of the challenges with IL-2 over the past three decades since its first approval in the 1990s, and we believe that the challenges have been addressed to many extent with the design of MDNA11. So I'm hoping that at the end of today's session, we will be able to restore conviction in the immense potential of a properly designed IL-2 in cancer immunotherapy, as was intended by the first developers of IL-2. What is different about MDNA11? As I said, our molecule is beta enhanced, and it's not alpha binding.
It is, as you can see from the picture or the cartoon on the left, it comprises an engineered IL-2 where we have inserted mutations to avoid binding to the alpha domain on T-cells, and therefore reduce vascular leak, reduce immune suppression, but enhance the safety of this drug, which has been a huge problem in the past. Second, to compensate for loss in alpha binding, we have enhanced beta binding, and the purpose there is to increase activation of the immune cancer-fighting T-cells, improve their memory, and of course, prevent exhaustion of natural killer cells. Finally, we have linked the IL-2 to human albumin, and the purpose there is to not only improve the pharmacokinetics of the drug, but also to accumulate the drug in the tumor and the tumor-draining lymph nodes. Overall, what we have done is created novel pharmacology with this engineered IL-2 with MDNA11.
As you can see on the left-hand side, or rather the right-hand side, native IL-2 will bind to the alpha domain, not as tightly to the beta-gamma receptor, which is expressed by the cancer-fighting immune cells, and therefore, the challenges that you see is that it will invariably cause safety issues, but also immune suppression. With MDNA11, we have reversed it, so we do not bind to the alpha domain, but instead bind with exceptionally high affinity to the beta-gamma receptor, and therefore are able to secure durable anti-tumor response, as you will see in today's presentation. If you look at IL-2, the one that was originally developed some 30 years ago, on the top left, you can see that the IL-2 will bind with extremely high affinity to the alpha receptor, or CD25.
On the bottom, what you see is the same IL-2 binding with relatively weak affinity to the beta domain. In essence, the native IL-2 tends to bind tightly to alpha, but not to beta. Over the years, what has happened is to, in order to generate a safer version of an IL-2, various companies have attempted to reduce binding or block binding to the alpha domain. In the end, what happens is you get the binding of an IL-2, as you see on the top right, but very weak binding to the beta receptor. What we have done is change that paradigm completely, so that we now have enhanced binding to the beta receptor, and that therefore makes it a beta-biased and beta-enhanced binding with no alpha binding.
In addition to changing the binding affinity, what we have been able to do is reduce alpha binding, and therefore, as you can see on the left of this particular slide, that the signaling is dramatically altered when you make that change on native IL-2. When you remove the alpha binding capacity of native IL-2, which is what a lot of other companies have done, is you can see the curve shifting to the right, and in that case, showing that the drug is becoming less active in stimulating cancer-fighting immune cells. On the right plot, on the other hand, what you see is MDNA109, or H9, it was as published, with removing alpha binding, you are able to maintain the tight signaling, binding, and therefore activity of the drug without sacrificing the activity.
Basically, what we are doing is bypassing the need for alpha binding, and therefore stimulating CD25-positive-activated CD8 T-cells without the need for alpha binding. When we look at the very first big failure in the IL-2 space, particularly bempeg as a good example here, which contained native IL-2 with pegylation that the pegs, that were six of those pegs, would gradually be released. From the phase III study that failed, basically showing that the Treg population, as you can see on the left of this plot, substantially increases in population, whereas that of CD8, NK cells, et cetera, remained relatively modest. Not surprisingly, therefore, what you did see with this combination of bempeg with nivo was simply that the combination of bempeg and nivo was worse than nivo on its own.
Then there were attempts to really avoid these linkers or pegs from coming off, and therefore there were better designs to really permanently block alpha binding, which was not the case with bempeg. What you see is, as an example, nemvaleukin essentially did that. They limited alpha binding very efficiently, unlike bempeg, but did not do anything to enhance beta binding. Therefore, what you see on the plot at the bottom from the human clinical studies is that you do achieve those red boxes or squares on the plot are showing that your Tregs are not expanding, which is perfect. However, you are seeing more of an expansion of your NK cells, but not of your CD8 T-cells. Therefore, in the end, two phase registration trials for melanoma and ovarian cancer, both of them failed due to poor activity of this particular version of IL-2.
Non-alpha without beta enhancement was not only a failed program with Mural or Alkermes, but similar attempts were made with Xilio, with Synthorx, Cue, et cetera, where similarly the programs could not progress because of lack of single agent activity. We, on the other hand, with a beta-enhanced design, as you can see on the figure on the left, the Treg activity is substantially diminished. We do see expansion of NK cells, but what we do see is substantially greater boost of the cancer-fighting effector CD8 T-cells than those of NK. With this flip that you see, the switch over, we have been able to demonstrate compelling single agent activity in a checkpoint refractory setting.
With this, we have been able to overcome the need for alpha binding, and as you can see, not only did we increase the number of CD8 T-cells, but we are substantially expanding the population of high-quality cancer-fighting immune cells, including CD8, CD25 positive activated CD8 T-cells. What you see on the left is data from 40 patients, and we have seen significant expansion of CD25, TCF, or stem-like CD8 T-cells, et cetera, including memory cells, et cetera. Moving on to essentially what others have shown, not Medicenna, but this is independent labs, clearly showing that beta-enhanced IL-2 does provide much better outcomes, including more recently on the top left, work done at BioNTech to show that an IL-2 which has beta-enhanced is much better when combining with mRNA cancer vaccines.
With that, I'll pass it on to Dr. Tawbi and his discussion on how MDNA11 could play a role in cancer immunotherapy. Dr. Tawbi?
Thank you so much, Fahar, and thank you for the very kind introduction you gave about me. I'll actually take a minute here to share with the group why I'm so excited about this particular IL-2 agent. As you heard from Fahar, this is showing activity in places that we really hope IL-2 will be able to really make a huge impact. I'll share a couple of things. I've been personally in melanoma drug development and IO drug development since 2005, and so have really witnessed the power of interleukin-2, and we'll discuss that in a little more detail. When I started treating melanoma patients, it was the only thing that could cure patients. We know that that's an FDA-approved approach and a powerful one. The second thing I'll say is I've been involved very much in FDA approvals.
I've been an FDA reviewer for multiple drugs that got FDA approved and have personally filed FDA applications for drugs that became FDA approved. More importantly, in the last few even months, I've been on the advisory committee for the Replimune RP1 agent that got FDA approved. I think in a lot of ways, really thinking about how we can position this agent with the great activity that it's showing to be on that path, I think, is what we're here to discuss today. We're going to talk briefly about the fact that the unmet need is quite great, and the specific places where this has already shown activity are really quite relevant and immediately actionable.
We think about MSI-high tumors or MSS TMB-high tumors, and a lot of people say, "Well, single-agent checkpoint inhibitors have activity there, and is this a space that we could really make an impact?" The truth is, it is really remarkable that these cancers, because of the high tumor mutational burden, because of the presence of so many mutations, do end up responding nicely to checkpoint inhibitors. As I told you, I have been in melanoma for 20 years. That is a disease that has a very high tumor mutational burden, and a lot of our patients do not respond. So already, we are very impressed with the fact that checkpoint inhibitors work in ICI-naive settings, but there are actually quite significant caveats.
One is the fact that if those cancers, and a lot of them are GI as you see here, if they have liver metastases, suddenly that activity drops dramatically.
As you see on the left lower corner, while you report high response rates in these patient populations, as soon as you include liver metastases, we know that is a place that is quite resistant to checkpoint inhibitors, so that response rates drop even in the naive population. More importantly, we see that patients progress after responding. This is the secondary resistance to checkpoint inhibitors. Once that happens, the response rates drop also to the 10%-12% range, which is almost identical to what you get from a random phase I trial. So really kind of a place that needs improvement. If you kind of contextualize that for metastatic MSI-high GI tumors specifically, there is about 25% that will have primary resistance, and then patients that do respond can still progress up to 44%.
You are talking about three-quarters of those patients that will need additional therapy and additional treatment. As you see on the right side, as soon as you include liver metastases, those numbers become even more daunting. As I mentioned, in the presence of liver metastases, the odds of having a primary resistant disease more than double. If you have received one prior line of therapy, again, the chance of secondary resistance is almost close to double as well. This is where this study and this ABILITY-1 that you will hear from André a little later, and specifically MDNA11, not only has included those patients, but actually has shown activity both as a single agent, as a combination regimen in those specific diseases. On the one hand, I think the unmet need is a very big opportunity, which I will talk about in a minute.
We do need kind of to see the disease control, and you see that monotherapy has 35%-45% response rate, either as a monotherapy or a combination. Importantly, that ability to have a response in liver metastases, which almost all of those patients that have liver metastases, a lot of drugs fail exactly at doing that, and I think that really highlights the biological impact of MDNA11. The second thing I really wanted to highlight is I really strongly believe in the accelerated approval path, and the FDA has kind of persisted in making this available when you actually go for a population that has a high unmet need, you show activity, and you can sometimes, with a single-arm trial, really get through to a registration path.
I am showing here specifically this population we are discussing, the MSI-high or TMB-high, where we now know it is a tumor-agnostic approval for several of the checkpoint inhibitors, and this actually offers an opportunity. The FDA is really very excited about being able to approve things that are tumor-agnostic, especially if biomarker-driven. I think this idea that you could check the TMB, the MSI, and determine that those patients would be appropriate, and then you have a drug that has activity both as a single agent and as a combination, I think really improves the chances of this kind of following that accelerated approval path. The third thing I want to discuss is melanoma, right? So I have been dealing with melanoma for almost two decades, and I can tell you that is a tumor with a high tumor mutational burden, but not every patient responds.
Most of it, as you will hear a little bit from the data that André will show, it is not about having mutations. It is also very significantly about the tumor suppressive microenvironment and about antigen presentation. Those things, if you could really enhance them with MDNA11, you could utilize the fact that those mutations exist to ignite an immune response. In melanoma, we know that half of our patients progress in the first line as a primary resistance, and then there is still about half of those that respond that could still progress. In that space, there are only two currently FDA-approved regimens, Amtagvi, the TIL therapy, and RP1. Amtagvi, TIL therapy is a really, really tough thing to do. Highly select population. There are only so many patients you could treat. They have to have stable disease, not very progressive, highly progressive disease.
The response rates are actually somewhat disappointing. Important FDA approved, by the way, 130 patients to get the accelerated approval, right? Also, a regimen that is not applicable to most of our patients. RP1, again, I was part of the advisory committee that convinced the FDA to approve this regimen. I think it is going to be helpful to patients, but it is also limited in its activity. It is injectable, so it requires a procedure to be done, and you will see that its activity is helpful but relatively limited. I think that is where places MDNA11, it is already something we know in melanoma. It was the only thing that cured patients. You could administrate it intravenously, and basically will be available to a large proportion of patients, especially as you will hear the safety profile allows it to be applicable across the board.
When we are comparing some of the data you will see from André to what has been already published from the IGNYTE trial, we want you to take a close look at the patient characteristics. You will see that this ABILITY-1 really went after some of the toughest patients. All of them stage 4, liver metastases up to 30%, and 77% had already seen prior PD-1 and CTLA-4, PD-1 LAG-3. That is, I think, very important to contextualize the results. When you place what you are going to see in the context of what is approved in melanoma, you will see that Amtagvi and ipi/nivo, RP1, it is all about 30%, but each of them come with a very select population, and again, patients that are not progressing very rapidly, 24% for RP1.
We have with monotherapy in a secondary resistance cohort, you could have a 30% response, up to 40% with combinations. Remember, this is a population that if you compare across trials, it is a population that is a lot tougher than even what was included in those. I will end with the fact that I really do believe that this beta binding has really kind of highlighted the specific role of IL-2, and I think the impact on the tumor microenvironment is going to be relevant for both secondary resistance populations and primary resistance populations, specifically in the fact that it is not enough to have the tumor antigens or neoantigens from mutations, but also to be able to impact the immune microenvironment, to be able to allow more antigen presentation, and kind of to reverse exhaustion that already exists.
You see from these preclinical trials the impact of interleukin-2, and the fact that it is so much more decreased in patients that have already been progressing. Then if you add MDNA11, and this is kind of a couple of some of the data that you are going to see, you increase exactly that effector cell population, and you exert immune control. From my perspective, as you are going to see shortly, both the biological impact, the clinical context, and now the clinical activity from ABILITY-1 really positions this agent to be the success we have been really waiting for in the IL-2 space. With that, I am going to turn it over to Dr. Mansinho so that he can share with you the data from ABILITY-1.
Thank you, Hussein. Thank you, Fahar, for the also kind introduction. Good morning, good afternoon to everyone. Building on the biological rationale Fahar just shared and these post-ICI clinical gaps Hussein just highlighted, and being that we are a phase I unit, I am delighted to walk you through the clinical data of the ABILITY-1 study of MDNA11 and try to show you why we are so excited with these results. This slide shows our study design. ABILITY-1 evaluated MDNA11 across two parallel arms, monotherapy on the left and combination with pembro 400 mgs every Q6 weeks on the right. In dose escalation, we reached 120 micrograms per kg. This was done every two to three weeks without hitting a maximum tolerated dose. This defined our biologically effective dose range at 60-120 micrograms per kg.
Ultimately, we selected the 90 micrograms per kg every two weeks as our recommended expansion dose for both arms. This is due that we did not see an increase in the expansion of the T-cell population or the target populations that we were assessing on that particular dose increase. Additionally, I can tell you that by personal experience and by having treated some patients here, 120 tends to be not as tolerable as the 90, so this seems like a rational approach. Notice our expansion cohorts, monotherapy focus on secondary ICI-resistant melanoma and MSI-H, dMMR, or TMB-H tumors, while the combination tackles primary ICI-resistant melanoma, MSI-H, or tumor mutational burden high tumors as well, and secondary ICI-resistant MSS endometrial cancer. Oh, sorry.
Out of the 152 enrolled patients, and this data cutoff was done on October 28th, we have 118 patients that are efficacy evaluable within the biological effective dose range, 53 on monotherapy, 65 on combination. Within this population, our core efficacy cohorts comprise approximately 36 patients with MSI-H or TMB-H tumors, 26 with cutaneous melanoma, and nine with microsatellite stable endometrial cancer. Note that the TMB-H is strictly defined here, as per the last FDA definition. Microsatellite stable tumors with TMB over 13 mutations per megabase. The MSI-H and TMB-H groups are mutually exclusive, and this is an important note. This slide summarizes safety across these monotherapy and combination patients. Unlike first and second-generation IL-2s, as Fahar mentioned, MDNA11 has a remarkably clean, I would say predictable as well, outpatient profile. This is important.
We saw zero DLTs, so no dose-limiting toxicities through the 120 micrograms per kg, zero grade five events, and over 90% of treatment-related adverse events are either grade one or two , mostly transient infusion reactions, pyrexia, chills, nausea, that resolve, and within my clinical experience, I would say after the first 48 hours. Grade three or four events, and this is important to notice, are predominantly asymptomatic, so essentially reversible liver enzyme elevations, no Hy's law, which is important, with only a single transient grade four CRS in a patient which already had baseline hypotension. I think that is notable. That resolved also quick, in four days. I would say that adding pembrolizumab introduces no relevant safety signals. Let us look first at the MSI-H and MSS/TMB-H gastrointestinal cancers. This slide, I think, is particularly important because it highlights just how heavily pretreated our 20 evaluable GI patients are.
First, this is a true third-line, fourth-line salvage population. We see that we have a median of three prior systemic lines, up to 10, 45% having received four or more prior regimens, and 65% having progressed on prior checkpoint blockades. This includes 82% on the monotherapy cohorts. This is very important to establish the baseline characteristics. Second, as you can see here as well, baseline tumor is relatively high, with a median sum of diameters of 75.5%, 85 on the monotherapy. Third, as Hussein highlighted, 35% of our patients entered with active liver metastasis. We know that this is a major driver of immunotherapy resistance, and we will see further on ahead why this is important for these patients. Across all 36 evaluable MSI-H or TMB-H solid tumors, we can observe a 28% overall response rate, so almost a third.
Most importantly, 78% disease control rates across six tumor types. If you focus and look at the coral bars here, which represent GI tumors, versus the blue non-GI bars, we see that responses are heavily enriched in the GI subset, where we achieve a 40% overall response rate, so eight out of 20 patients, and an 80% disease control rate. If we zoom in into those 20 GI patients that we presented on the last slide, and if we take into account what Hussein just presented, historical post-ICI rechallenge or salvage chemotherapy yields an average of 11%-13%. Let us focus on the 10% number here. We see that MDNA11 monotherapy achieves a 36% overall response rate, with a very good disease control rate as well, while MDNA11 plus pembro achieves a 44% overall response rate.
If we look at the waterfall plot as well, 55% of the patients achieve tumor regression. As you can see here, as shown by the gray boxes along the bottom, these responses are occurring directly in ICI refractory patients, which are pancreatic, biliary, colorectal cancers, alongside, and this is very important on the palliative setting, durable, stable disease that exceeds almost 50 weeks. This is really important when we look at the palliative setting. I think this slide here captures what matters most in second or third line plus GI oncology patients, which I think is duration of response. I know in late-line disease, if we tend to compare this with chemotherapy, for instance, we know that brief chemotherapy shrinkage rarely alters survival. What patients need in this setting is durable immune memory, vaccine-like memory.
As you can see here, median duration of response is not yet reached. This is greater than 32 weeks, with four responses ongoing. If you look at the top two bars, our first MSI-H pancreatic cancer patients on monotherapy stopped treatment after 91 weeks, which remains in complete remission. So treatment-free remission for 138 weeks. This is actually a very long time mark for a pancreatic cancer patient. Right below that, we see a TMB-H CRC patient in combination that continues to experience response deepening of treatment, with a duration of response that exceeds 78 weeks right now. Let's see the scans for that top swimmer plot patient. Stage 4, MSI-high pancreatic cancer, liver mets, very important, who failed three prior lines. Every treating oncologist know that this is a very bad prognostic patient, and we had a very rapid primary progression on pembrolizumab.
Six weeks after failing pembrolizumab, single-agent MDNA drove a 100% complete regression of both liver target lesions, as we can see here, leading to that ongoing treatment-free remission that we saw in the swimmer plot. Really remarkable patient and a very good case, of course. This slide shows a second monotherapy hepatic responder. As we can see here, stage 4 MSI-high as well, cholangiocarcinoma, nearly 12 centimeters of baseline tumor burden. Primary progressor as well, first-line GemCis and durvalumab, and on third line, MDNA11 monotherapy, this large liver lesion shrank significantly. This is a confirmed PR with an approximately 47% target lesion reduction that remains ongoing past 24 weeks. A third case, and this is an MSS CRC.
We can see here, TMB-high patient, stage 4 colorectal cancer, importantly MSS patient, treated in the sixth line setting after failing five prior regimens, including, this is important, primary resistant to pembrolizumab without a single prior objective response. If we see at the tumor growth index and previous line responses, this is very remarkable. With MDNA11 plus pembrolizumab, it achieved a confirmed PR, 84% target lesion reduction, and complete reduction of non-target lesions. This duration of response already exceeds 32 weeks, and this is really remarkable on this clinical setting of MSS colorectal cancer. Just to note why it is important to take into account that RECIST might not always apply to these patients. I think this is important because some patients might derive clinical benefit even after classical immunotherapy progression. This slide illustrates what we call the classic immunotherapy pseudo-progression.
This was on MDNA11 monotherapy, and in a chemotherapy-resistant MSI-high pancreatic cancer, what we see here is that at week eight, initial immune infiltration caused a significant, I would say, almost a third, 35% enlargement in a new liver lesion, b ut because the patient was clinically well, he had no, of course, options beside this clinical trial. Treatment continued, and by week 16, we can see the new liver lesion vanished, and the target liver lesions shrank by 35%. This is what we call an immune PR, and this is really notable. Most importantly, and in line with what [Hussein] said, we should pause on a moment to see this. I think this is one of the most remarkable charts in our dataset. We know that liver metastases are notoriously immunologically cold, nearly double the risk of primary ICI resistance in GI cancers.
Yet, across all four out of four evaluable patients here, MSI-high GI patients treated with MDNA11, eight hepatic target lesions, so in these four patients, they all regressed. And we have a 100% clearance of four liver lesions across two patients. I think this level of single-agent hepatic activity is truly differentiated, and so a very important information to highlight. Now, briefly on this slide and outside of GI tumors, just showing a very aggressive, I would say, PD-L1 negative, TMB-high, small cell neuroendocrine bladder cancer with a massive tumor burden, 16.2 centimeters of tumor burden after three prior chemo lines, so heavily pretreated. And rolling over from monotherapy to MDNA11 plus pembro, we can see that this pelvic mass shrank by 89% to 1.8 centimeters. And I would say this is a complete metabolic response in a PET scan. Duration of response also very large.
Again, it's very unlikely that a mass like this achieves CR on a CT scan because there is residual fibrosis. This is something that we see metabolically in the PETs more concretely. Now, turning to checkpoint-resistant stage 4 cutaneous melanoma. I would say, and remember how advanced this cohort is. Touseef presented this data previously. 100% stage 4 disease, 92% M1b/d, and 77% prior PD-1. This is patients that failed legal EP, and even here, MDNA11 monotherapy achieved a 30% overall response rate, a very high disease control rate as well, which I would highlight again, it's the more important endpoint when we look at the palliative second, third line setting, while MDNA11 plus pembro achieved an almost 40% overall response rate in a primary ICI resistance. After a 98-week complete response on monotherapy, 32 weeks of therapy, we see here the patient.
Let's see our swimmer plots in similar way to what we showed in the GI tumors. This underscores that curability is also a theme here. Across all 26 melanoma patients, the median duration of response is an impressive 68 weeks. The range is quite large, but we have three responses ongoing. And beyond our top patient who re-responded upon monotherapy retreatment, notice the second patient also achieved a very deep response after an initial radiographic progression. This is truly remarkable, and we'll show some cases as well with some liver lesions to highlight the activity of this drug. We can see here that our hepatic activity extends directly to visceral melanoma as well. This stage 4 M1c melanoma patient with primary progression after just one month of ipi/nivo, on second line MDNA11 plus pembro achieved a complete PR, 55% overall, with their liver metastasis also shrinking.
On the next slides, we see another primary ipi/nivo-resistant melanoma patient, also with massive hepatic involvement. A very large 16-centimeter liver mass, surging transaminases, so LDH around 600 units per liter. We know, and Hussein has a lot of experience treating melanoma patients, this is a very bad prognostic patient. And within eight weeks of treatment, we see that this mass shrank dramatically to 13 centimeters. And remarkably, I think the patient clinically improved, and we see that all the biologically laboratory values, AST, ALT, LDH, CRP, normalized to the upper limit of normal within 50 to 70 days. This rapidly rescued liver function in a patient that otherwise was very compromised. Now, let's just focus here on the MSS, microsatellite stable endometrial cancer, and we see that among 11 enrolled patients treated with MDNA11 plus pembro, the median prior therapy was three lines.
We see that 100% that progressed on prior ICI, and 82% had secondary ICI resistance. We did not exclude also aggressive histology, so we have aggressive serous carcinosarcoma subtypes, and crucially, we saw deep regressions, including a complete target lesion clearance in a patient who already had failed len/pembro. And focusing, I know this is, of course, less patients at the other cohorts, but the other waterfall plots show that across all 9 available patients, the confirmed overall response rate is 22%, and even in the secondary ICI-resistant disease, MDNA11 plus pembro achieved an almost one-third of confirmed overall response rates, with a very high disease control rates of 71%. As Hussein will highlight next, I'm sure, I think a 29% confirmed overall response rate in the post-ICI setting in these patients matches a 30% benchmark of len/pembro, with vastly better tolerability.
I would highlight that doing len/pembro is quite challenging, so I would say that given the toxicity profile that I know for this patient, is remarkably tolerable. This slide 54 confirms that these responses and disease stabilization are durable across high-risk histologies like uterine carcinosarcoma and serous carcinoma, extending from 24 to nearly 60 weeks on study. And I would end my part of the presentation by saying that we had a manageable safety and selective pharmacodynamics. The MDNA11 is well-tolerated, even through the 100 micrograms per kg, with no DLTs and robust expansion of memory and stem-like TCF1-positive, CD8-positive T cells. On MSI-high, dMMR, or TMB-high GI cancers, we have a 40% combined overall response rate, more than tripling the 11%-13% post-ICI benchmark, with a very, and this is very important, median duration of response that was not reached, so multi-year treatment-free remissions.
And I believe this is also something to highlight. We have unprecedented hepatic activity, so eight out of eight measurable liver target lesions regressed across four monotherapy patients with deep hepatic regressions. And I would say that in the ICI-refractory melanoma setting, 30% monotherapy overall response rate and almost 40% in combination in primary resistance with a 68-week median duration of response is quite remarkable. As well, and as I just showed in the last cohort, a 30% confirmed overall response rate with a 70% disease control rate in secondary ICI-resistant disease is also remarkable. And now I will hand the floor back to Dr. Hussein to put this data into the registrational context. Thank you.
Thank you so much, André. We do want to give you some time for questions, so I will be very, very brief. I think I made the case before that this is I mean, what you are seeing really is a validated target in the context of IL-2 itself. For several decades, we know that this can cure patients. The beta specificity is allowing this activity in the hardest cohorts, and you see patients with You have seen the liver metastases specifically for both MSI-H refractory patients and TMB-H refractory patients. If you place this in the context of currently available therapies, they are all in the 10% range or so, and we see both single-agent activity and combination activity to the tune of 40%.
I place this in the context of melanoma, 30% in secondary resistance and close to 40% in primary resistance in a population that is even significantly harder to treat than the RP1 cohort that showed a 24% response and got FDA approved. Maybe what is really shocking to me in a way, being an IL-2 person as well, is the fact that the tolerability of this beta specificity is allowing every two-week intravenous dosing at a high enough dose that we know biologically active. We did not have time to show you some of the translational work, and it is actually better tolerated than things like pembrolizumab and lenvatinib. I treat patients with pembrolizumab and lenvatinib for some of our brain metastases studies, and it is a very tough regimen, FDA approved in endometrial.
This comparison where you are actually showing a combination of an IL-2 with a PD-1 is in fact more tolerable than this combination that is FDA approved. With that, I will just turn it back to Fahar, and happy to help answer any of your questions as well. I think really the opportunity is really quite remarkable at this moment. Fahar, you are on mute, I believe.
I am on mute. Well, thank you very much, Hussein and André, for your thoughtful comments and really detailed presentation. I will not go through the key takeaways. I think you have all done a really good job in sort of messaging that story. I think, going forward, as far as the company is concerned with the next steps, clearly, we have all the patients being followed. We have another 15 or 14 patients without a scan, so we will be looking to solidify the durability of MDNA11 in each of the three expansion cohorts. With those data, we plan to have an end of phase I meeting with the FDA and see if there is a path forward for MSI-H or biomarker-driven GI tumors, and even advanced cutaneous melanoma, and perhaps even the endometrial cancer population that the data seems to mature.
Clearly, we think there is opportunity here to pursue accelerated approval. We are currently conducting a neoadjuvant study in cutaneous melanoma. We will have more data on that. And we think the potential is here not only to see if MDNA11 can be used in combination with checkpoints, but perhaps other treatment modalities, and also see if there is potential for us to partner with pharma to further advance this program. In the end, I hope that today's presentation provided us with a sort of a restored conviction with respect to the potential or immense potential of a properly designed IL-2 in cancer immunotherapy. And with that, I will pass the floor on for Q&A to the audience. Thank you.
Great. Thank you, Fahar. Yes, so at this time, we will be conducting a question-answer session with our speakers. So please hold for a brief moment while we pull for questions. So our first question comes from David Martin at Bloom Burton. Please go ahead, David.
Hi there. Can you hear me?
Yes.
Yes, we can.
Perfectly.
Okay, thanks for taking my questions. The first one is for the KOLs. As the analyses focused on specific tumor types and mono and combo therapies, N was relatively small for each group. In your view, are there enough patients in some of these groups to have strong conviction that ORRs will hold up in larger trials and that MDNA11 is competitively active?
I will handle that. Yes, thank you, David. I mean, I think the points we were making are kind of the fact that there are several shots on target. One is that you could go tumor agnostic biomarker-based with the TMB-H, secondary resistance, and also in combination with the primary resistance. That in itself is one path. Then you could actually differentiate into tumor-specific paths with melanoma, for instance, widely open for a registrational approach. Again, showing kind of the context of RP1 as it stands. I think the MSS endometrial as well is quite impressive. I will say that from an FDA perspective, in my opinion, the tumor agnostic biomarker-driven path is something that is probably going to be the most palatable because it has also that monotherapy activity.
You prove single-agent activity, you have combination activity, and you can be tumor agnostic and biomarker driven. Those are kind of all the checkboxes that the FDA needs generally. That would be my perspective. Remember, some of the accelerated approvals happened with 130, 140 patients, so we are not that far if we make a specific push in those spaces.
Okay, thanks. I do have one for the company, and then I will get back in the queue. Last week, Merck abandoned Sutro-partnered IL-2 drug. Has there been any changes or anticipated changes to your supply agreement with Merck?
Thank you, David. There has been no changes with respect to our collaboration with Merck. Their support continues, and we recently acquired additional supply from them as well. That's certainly not affected our program.
Okay, thanks. I'll get back in queue.
Thank you.
Thanks for the questions, David. Our next question comes from Andre Uddin at Research Capital. Please go ahead, Andre.
Thanks. Good morning, everyone. I just have a simple question. The data for the 20 heavily pre-treated patients with gastrointestinal cancers look very promising. Based on that data, do you think it would be worthy to explore the combination of MDNA11 and KEYTRUDA in a first and second line treatment setting? Thanks.
I can take that question. I would say that the benchmark is rather high in first line MSI-H tumors. If you look at the colorectal cancer data, we see the HW response rates and duration of treatment. I do not know if MDNA11 in a first-line setting would have that meaningful responses. In the ICI refractory setting, I am very positive that it will. I mean, we tripled the overall response rate. Even more importantly, the duration of response is quite remarkable, and we need to take into account this is a heavily pre-treated, highly refractory, and the majority of the patients did not have ICI previously. If we look at that data, we can reverse secondary resistance, and even in PDAC, for instance, we saw remarkable responses.
On GI cancers and moving forward to an agnostic approach, I would favor the refractory setting rather than the primary first-line setting. Yeah.
Okay. Thanks for that.
Thanks for the question, Andre. Our next question comes from Dev Prasad at Lucid Capital Markets. Please go ahead. Dev, you might be on mute.
Hi. Can you hear me?
Yes.
Hi. Thank you for taking our question, and congrats on the progress. I have a couple of questions. One is, the presentation showed 40% ORR in GI cancer versus 12.5% in non-GI. Do you believe there's a biological rationale for greater sensitivity in GI versus other, or is it too early to conclude? Then, in general, to Dr. Tawbi maybe, given the landscape in post-ICI, including TIL and RP1, how do you view MDNA11 efficacy and safety profile, and what level of ORR and durability would make a competitive treatment option? Thank you.
Yeah. Thank you, Dev. I mean, I think the couple of things you have to take into account is really the biology that we're targeting. To answer the first question you were specifically highlighting, I do think it's about being able to decrease the, to improve the CD8 positive T-cell infiltration. I think we need to improve antigen presentation, because those are tumors that already have a lot of neoantigens, but they may not be able to do as much antigen presentation. The impact on NK cells is going to be very important. In that context, I see the responses in GI malignancies that are TMB high or MSI-H are going to be very clinically relevant. That's in the first question. The second question around melanoma, I actually think there's a tremendous opportunity in the second line melanoma.
Cellular therapies are, by definition, only appropriate for a select population. I can tell you, at MD Anderson, we see over 1,000 new melanoma patients a year, and we're a high-volume center, and we end up treating about 100 patients with TIL therapy a year. We're trying to expand. Maybe we'll be able to get to 200, but a small, tiny proportion that ends up getting the cellular therapy. The newer therapies like TCR-T, you know, may be a little more available. Look at, for instance, IMA203, which is the cell therapy from Immatics. It's also HLA-A*02:01 restricted. I think MDNA11 sits in a space where it will be available for more patients with this activity, both as a single agent, as a combination. It'll be available to every patient that's ICI refractory.
Also remember one last point that Fahar made that I think is really critical for everyone to keep in mind. If this moves forward, it can be combined with other things, not pembro alone. It may actually be relevant for TIL therapy. Every TIL patient we treat with six doses of high-dose IL-2 inpatient right now, and that's hard. That's what limits the availability of this therapy. It could be that MDNA11 may actually be a better partner for TIL. There's a lot of opportunity to expand on its indications.
Great. Thank you.
Thanks for the questions, Dev. Our next question comes from Daina Graybosch at Leerink. Please go ahead, Daina.
Hi. Thanks for the questions. Maybe three for me. One just practically on TMB. I am wondering if this is tissue or liquid biopsy-based, given, you know, particularly in CRC, I think that the liquid has been showing better correlation with checkpoint sensitivity. The second question is if you could discuss why you think this particular IL-2 is giving effective responses in patients with liver mets. Fahar, I would be really interested in albumin and how albumin helps traffic to the liver, and if you think that the specific construct over other, let's say, bispecific IL-2s biologically has better rationale for the liver activity. Then finally, for the KOLs, we also saw some data with Werewolf's IL-2 at SITC, and they have taken almost an opposite approach with a masking in a wild type alpha, and also has some single agent responses.
I wonder if you could just talk about the two datasets taking two different approaches and how we should think more broadly about IL-2 targeting. Thank you.
Maybe I will address the albumin specificity and the relevance to liver, and I will turn it to André for the rest. I actually think those are exactly my thoughts, that the albumin may be allowing for more of the reticuloendothelial system to take this up. You are almost targeting the myeloid compartment. You are almost targeting exactly the things that lead to the most immune suppression in the liver. The Kupffer cells are part of the reticuloendothelial system. It is possible that they are taking up this agent at a kind of more significantly than other cells in the tumor microenvironment. I am really intrigued about this liver activity, and we have been talking to Fahar about maybe even biopsying normal liver in these patients to try to understand that component of the science.
I do think there is a definite component of that that is helping to see this activity we see. I will turn it to André to address the rest of your question.
Yeah, I mean, looking at the WTX-124 candidate that was presented at SITC and not focusing on the non-small cell lung cancer data, focusing exclusively on melanoma, I have a difficult time always comparing different trials, different populations. This needs to be taken into account with a grain of salt. I f you look at the overall response rate on the primary resistant or ICI-resistant melanoma patients, it is half of what MDNA11 showed. I would say that the biological approach of MDNA11, from a rational or a biological rational standpoint, is better designed. Of course, this is limited data, limited data sets. It is pretty hard to draw a conclusion from here, but this is my first impression.
André, could you sort of talk about the blood biopsy approach for TMB-H selection? Because obviously in the study, we did not use blood-based TMB.
Yeah, I mean-
Yeah
When we talk about the liquid biopsies, we have a more accurate figure of what the current picture is, and we know that on these patients which have a high chromosomal instability, mutations tend to evolve as stage 4 disease progresses. They tend to accumulate more mutations. Ultimately, that's what drives progression. Of course, liquid biopsy, and we know that the majority of tissue that is enrolled on these trials are either from the primary or from a diagnostic biopsy. Of course, liquid biopsy might reflect the actual panorama, but we have some limitations. I mean, scaling is an issue, so not all patients have accurate liquid biopsy.
These days, I think the ones that do with a good cellularity and if we identify very high percentage of allelic fractions that are really a picture of what the disease reflects right now, yes, I think we can select and enrich the patients in a liquid biopsy. Given all the limitations, I wouldn't say it's a straight pathway forward still, but I think as sensitivity increases, it's probably the way to go.
Thank you for the questions, Daina. Our next question comes from Chad Messer at Lake Street. Please go ahead, Chad.
Great. Thanks for taking my question and for a great presentation. I know we're over time here, so maybe just one for me. I'm interested in the sort of dose-finding work, and whether the KOLs think we're kind of covered here if we wanted to go into the targeted population. I know, Dr. Mansinho, you commented that 120 was less tolerated in some of the melanoma patients, but we didn't have any. If we are actually going after the targeted patients, we didn't have any there. Do you think we've got Optimus covered with the data, or would a little bit more dose-finding work be necessary if you're going into the GI group first?
Well, if I may tackle that question, I would say looking at the preclinical data that we did not show here, or the pharmacodynamic data, what we see is that when we increase the dose from 90 - 120, we do not have any biological or at least significant biological effect. In terms of cell expansion, at least at the peripheral level, we do not want to see an increase on the target populations. Of course, biopsy work would be useful to see if the infiltration increases. I would say that from my experience, and this is not reflected on these cohorts, but a renal cell cancer that I included in this trial was on the 120 every three weeks, and what I see is that the tolerability is quite, or it is significantly different.
The patient has the side effects for more time, fatigue, essentially some kind of chills and pyrexia, that with the 90 tend to last 48, 72 hours in the first cycles at most. With the 120, the patients reported those complaints for about a week. What we saw with the dose decrease was that this kind of side effect profile vanished, so the tolerability improved quite remarkably. I think Fahar might comment on that, but we saw during the course of the trial some patients decrease from 120 - 90, but none from 90 below that. I would pretty much be convinced that given the efficacy that we are seeing and the tolerability of the 120, 90 is the way to go.
I would just add to that, I completely agree with André, and I think from an Optimus perspective, we are covered because of the dosing of IL-2. You actually need to consider two things. The fact that you want to do repeated dosing and for people to tolerate it a little bit longer term, you do not really want to be at the DLT or close to it. I like the idea of being able to be manageable grade 1, 2 toxicities. Second is kind of with IL-2, we have been burnt with the high doses. I mean, we know that this is beta-specific, but it is not the better answer to give a higher dose. Sometimes that is actually what resulted in previously negative outcomes.
I think the translational data from ABILITY-1 is very comforting to me as a translational scientist in seeing that we are seeing the impact that we want to see at those doses. There is a dose response if you look at the translational data as well.
Thanks.
Thank you for the question, Chad. Our next question comes from Mayank Mamtani at B. Riley. Please go ahead, Mayank.
Hi, [Mayank Mamtani] here. Thanks for taking our question. For Dr. Fahar, most of the data here is in KEYTRUDA, but we also know that the NEO-CYT data, the NEO-CYT is going on where we're also testing with OPDIVO. Do you think MDNA11's benefit is tied to a specific PD-1, or do you expect it to combine with any PD-1, including the newer PD-1/VEGF bispecifics that we're seeing? Do you have any preclinical or clinical data for that? Also, for Dr. Tawbi, I think you may have hinted at this, but for patients who've progressed on PD-1 plus CTLA-4, we know that TIL therapy is now an option, but it's also kind of complex and limited to specialist centers. Where would you place a ready-to-use IV therapy like MDNA11, and what response rate and durability would change your practice or other physicians' practice?
Thank you.
Well, thank you for your call, Mayank. Just with respect to the first part of the question regarding the NEO-CYT study specifically, obviously it's very early, but we've tried different versions of checkpoints, and we haven't seen much difference. Even when we create bispecific versions of checkpoints with pembro or nivo, we basically see very similar profiles with respect to safety, PK, PD, et cetera. With respect to the human data, we obviously don't have much experience with nivo. That study has just started. The intent here in the combination study with MDNA11 and nivo is to really compare pathological responses in two different cohorts, namely MDNA11 plus nivo versus the current gold standard, which is nivo plus ipi.
We will get more data on that towards the second half of next year, and we will obviously get a chance, particularly with the fact that we have better access to tumor, et cetera, to really analyze the combination in a much better way. I don't think, at least my thinking is that the checkpoint inhibitor selection should probably have a similar effect irrespective of which brand you use. I'll pass it on to Hussein if he has some other thoughts.
Yeah, I mean, my position on the second line setting in melanoma has been publicly stated at the advisory committee. I think a 30% response and of a tolerable regimen that could be widely available to patients would very quickly enter clinical practice. I mean, if you look at nivolumab, the person that led its FDA approval in the first-line setting, I almost never use it in the second line setting because it has a 10%, 12% response rate. If I have checkpoint plus MDNA11 that gives me a reliable 30% that is tolerable, I'll go for that. I think the presence of other things like TIL therapy and RP1 would be immediately relegated if MDNA11 makes it through.
Thank you.
Thank you for the question, Mayank. Fahar, this concludes our verbal portion from the analysts. I'll turn it back to you.
Well, thank you very much for all of you being part of the conversation today. We've obviously received several other written questions. We certainly do not have the time to go through them. I really appreciate Dr. Tawbi and Dr. Mansinho for making themselves available despite their busy schedules for another extra 15, 20 minutes. Thank you very much. Really appreciate your thoughts, your feedback, and those that we could not answer those questions, we'll certainly reconnect with you guys by email or phone. Feel free to contact us separately. Thank you all, and good day to all of you.
Thank you so much. Take care.
Thank you.
Thank you. Bye-bye.